Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine
Emory University · with National Institute of Mental Health (NIMH) · NCT05327699
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–65 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Early Phase 1
- Target enrollment
- 140
- US sites recruiting
- 1
- Study start
- November 8, 2022
- Record last updated
- May 26, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The main purpose of this study is to investigate the effects of ketamine on decision-making and emotion processing in a sample of individuals diagnosed with Major Depressive Disorder (MDD).
Being studied: Ketamine; Placebo
Conditions: Major Depressive Disorder
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
MDD Patients
- willing and able to give written informed consent
- men or women, 18-65 years of age
- primary diagnosis of DSM-V MDD, current, as diagnosed by the SCID-I
- score of ≥20 on the Beck Depression Inventory, which will include patients characterized as having "moderate/severe" (20-28) or "very-severe" (29-63) depressive symptoms
- off all antidepressant therapy for at least 8 weeks prior to the baseline visit
Healthy Controls
- willing and able to give written informed consent
- men or women, 18-65 years of age
Exclusion Criteria
MDD Patients
- history of any bipolar disorder or psychotic disorder
- active psychotic symptoms of any type
- substance abuse/dependence within 6 months of study entry (as determined by SCID)
- unstable cardiovascular, endocrinologic, hematologic, hepatic, renal, or neurologic disease (as determined by physical examination and laboratory testing), including upper respiratory disease or asthma, glaucoma or porphyria.
- active suicidal ideation as determined by a score ≥3 on the Columbia Suicide Severity Rating Scale (C-SSR)
- use of any recreational drugs as confirmed by urine drug screen at the time of scanning
- pregnancy or lactation
- use of glucocorticoids at any time during the study
- Raynaud's disease that may interfere with the cold-pressor
- contraindications for MRI
- MMSE score \<28
- elevated blood pressure prior to infusion (systolic > 160 or diastolic >100)
- history of treatment resistance as determined by ATRQ
- prior adverse reaction to ketamine
- use of antipsychotic medications
- use of greater than 2mg daily of lorazepam or similar benzodiazipine.
- Regular smoker as self-reported
Healthy Controls
- evidence of any psychiatric disorder with exception of specific phobia, and no history of any psychiatric disorder except mild past substance use disorder as diagnosed by the SCID-I
- history of any substance abuse within the last 6 months
- use of any recreational drugs as confirmed by urine drug screen at the time of scanning
- pregnancy or lactation
- use of glucocorticoids at any time during the study
- Raynaud's disease that may interfere with the cold-pressor
- contraindications for MRI
- MMSE score \<28
- Regular smoker as self-reported
Recruiting US locations
Emory University
Atlanta, GA 30322
Site contact: Michael Treadway, PhD · (404) 727-7541 · ketaminestudy@emory.edu
Study contacts (from the official record)
- Michael Treadway, PhD · (404) 727-7541 · ketaminestudy@emory.edu
Similar studies in Georgia
All mental health studies in Georgia →- RecruitingPhase 1Overnight stay mentioned
A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia
Leal Therapeutics, Inc
- Location
- Decatur, GA + 9 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingPhase 1Overnight stay mentioned
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
BioXcel Therapeutics Inc
- Location
- Decatur, GA + 3 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingHealthy volunteers
Observational Study of Decentralized Urine Optical Interaction Patterns Associated With Environmental Microplastic and Nanoplastic Exposure
Ecotera Health LLC
- Location
- Atlanta, GA + 50 other US sites
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersPhase 3
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
Reviva Pharmaceuticals
- Location
- Atlanta, GA + 16 other US sites
- Eligibility basics
- Ages 18–65